ABSTRACT
We use an individual based model and national level epidemic simulations to estimate the medical costs of keeping the US economy open during COVID-19 pandemic under different counterfactual scenarios. We model an unmitigated scenario and 12 mitigation scenarios which differ in compliance behavior to social distancing strategies and to the duration of the stay-home order. Under each scenario we estimate the number of people who are likely to get infected and require medical attention, hospitalization, and ventilators. Given the per capita medical cost for each of these health states, we compute the total medical costs for each scenario and show the tradeoffs between deaths, costs, infections, compliance and the duration of stay-home order. We also consider the hospital bed capacity of each Hospital Referral Region (HRR) in the US to estimate the deficit in beds each HRR will likely encounter given the demand for hospital beds. We consider a case where HRRs share hospital beds among the neighboring HRRs during a surge in demand beyond the available beds and the impact it has in controlling additional deaths.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors would like to thank members of the Biocomplexity Institute at the University of Virginia (UVA) for useful discussion and suggestions. We also thank the staff members at the UVA's high performance computing center and at the Pittsburgh Supercomputing center for providing the much needed high-performance computing resources. This work was partially supported by National Institutes of Health (NIH) Grant R01GM109718, NSF BIG DATA Grant IIS-1633028, NSF DIBBS Grant ACI-1443054, NSF Grant Number OAC-1916805, NSF Expeditions in Computing Grant CCF-1918656, CCF-1917819, US Centers for Disease Control and Prevention 75D30119C05935, DTRA subcontract/ARA S-D00189-15-TO-01-UVA, and a collaborative seed grant from the UVA Global Infectious Disease Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsoring agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The work does not include any human subjects.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.